Health officials in California have released the first ever “cost-benefit analysis” of the state’s medical marijuana program.
The analysis, by the California Department of Public Health, showed that the cost of prescription medication and related tests and lab tests are expected to increase by between $4.4 billion and $6.6 billion over the next 10 years.
It comes after the state announced plans to phase out all prescription drug coverage for the sickest patients by 2022.
The analysis estimates that patients will spend an additional $2,000 per year on medication costs and testing.
This will be offset by savings from lower prescription drug prices, the analysis said.
The cost of the cost-benefit analyses will be released at the California Health Care Cost Containment Summit next month in Sacramento.
Dr. David Mello, director of the California Medical Cannabis Program, said in a statement that the new analyses show that the program is working.
“We know that there are very serious problems that are happening,” he said.
“We know we have the right people to take care of patients.”
The program is designed to help patients with chronic diseases that require expensive medical care and has proven to be a success, the statement said.
“The vast majority of the people who need our help are doing well and their health is improving.
It’s important to show that they are getting the care they need.”
The state’s goal is to see that more than 95 percent of Californians get at least some prescription drug and related testing by 2020, and that by 2022, 80 percent of people eligible for the program get access to it.